apcin

Apcin is a potent and competitive inhibitor of anaphase-promoting complex/cyclosome (APC/C(Cdc20)) E3 ligase activity. Apcin competitively inhibits APC/C-dependent ubiquitylation by binding to Cdc20 and preventing substrate recognition. It acts by blockin

Apcin-A is an anaphase-promoting complex (APC) inhibitor. It interacts strongly with Cdc20 and inhibits the ubiquitination of Cdc20 substrates. Apcin-A can be used to synthesize the PROTAC CP5V.

Apcin A HCL is an anaphase-promoting complex (APC) inhibitor. Apcin-A HCL interacts strongly with Cdc20, and inhibits the ubiquitination of Cdc20 substrates. Apcin-A HCL can be used to synthesize the PROTAC CP5V.

Tapcin is a dual inhibitor of topoisomerase I and II, with IC50 values of 203 nM and 71 nM, respectively. It effectively inhibits the proliferation of cancer cells such as A-375, HeLa, Huh7.5, U2-OS, A549, Caco-2, and HT29, with IC50 values of 441, 1.04, 40.5, 0.002, 0.006, 0.287, and 0.842 nM, respectively. Additionally, Tapcin demonstrates antitumor activity in HT29 xenograft models.

Kynapcin-13 acts as a non-competitive inhibitor of prolyl endopeptidase (PEP) activity, with an IC50 of 76.80 μM, and exhibits weaker inhibitory effects on other serine proteases.

Kynapcin-28 is a non-competitive inhibitor of prolyl endopeptidase (PEP) with an IC50 of 76.80 μM and exhibits weak inhibitory effects on other serine proteases.